Histogen Shares Additional Emricasan Data From COVID-19 Study

Histogen Inc HSTO and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients.
As previously reported, emricasan was shown to be safe and well-tolerated during the 14 days of dosing and at the day 45 follow-up, compared to placebo. No serious adverse events were reported.
Further analysis of the laboratory and exploratory biomarkers unveiled potential mechanisms of COVID-19 and how emricasan blocks process to prevent disease progression.
First, in the emricasan cohort, there was an increase in certain blood immune cell numbers, which play an essential role in immunity against viruses.
Second, patients that received emricasan showed normalization of several serum markers related to increased risk for blood clotting that is typically elevated in individuals with COVID-19.
Third, substances that leak from dying cells in the body decreased and normalized in the emricasan cohort.
The above findings correlated with trends toward better immunity to SARS CoV2.
Price Action: HSTO shares are down 3.35% at $0.81 during the market session on the last check Monday.